Pioneering Tomorrow’s Cures, Today.
Iterion Therapeutics is a clinical-stage, biopharmaceutical company dedicated to revolutionizing healthcare through novel drug discovery and innovation.
Tegavivint in the Clinic
Iterion is enrolling a company-sponsored clinical trial in hepatocellular carcinoma, an indication where ~40% of patients harbor a Wnt/beta-catenin mutation and there is significant unmet clinical need. Iterion has already established tegavivint safety, pharmacodynamic, and clinical activity in a completed Phase 1 clinical trial.
The company also has deep collaborative relationships with leading institutions studying tegavivint in complementary investigator-sponsored trials.